Editas Medicine

## Overview Editas Medicine is developing CRISPR genome editing medicines for ocular, hematologic, and oncologic diseases. Tailored for modern biology and life science teams. ## Key Highlights - In vivo CRISPR trial EDIT-101 targeting LCA10 inherited blindness. - Allogeneic CAR-T programs leveraging CRISPR for next-gen immunotherapy. - Manufacturing partnerships delivering clinical-grade editing. ## Ideal For - Clinicians monitoring ophthalmology and oncology gene editing - Biotech investors tracking CRISPR clinical progress - Researchers collaborating on CRISPR-based therapies ## Quick Links - Official site: [editasmedicine.com](https://www.editasmedicine.com/) - Add to BioDir collections to track updates and collaborators.